American Century Companies Inc. Trims Stake in Medpace Holdings, Inc. $MEDP

Key Points

• American Century Companies Inc. reduced its position in Medpace Holdings, Inc. by 21.0%, now holding shares worth $3.41 million after selling 2,979 shares in the first quarter.
• Multiple large investors, including Northern Trust Corp and Ameriprise Financial Inc., have recently increased their stakes in Medpace, demonstrating significant interest in the company as 77.98% of the stock is owned by institutional investors.
• Analyst ratings for Medpace are mixed, with two Buy ratings, nine Hold ratings, and three Sell ratings, and a consensus target price set at $406.60, reflecting varied expectations for the stock's performance.

American Century Companies Inc. trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 21.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,188 shares of the company's stock after selling 2,979 shares during the period. American Century Companies Inc.'s holdings in Medpace were worth $3,409,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Whittier Trust Co. raised its holdings in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares during the last quarter. Benjamin Edwards Inc. raised its holdings in shares of Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock valued at $366,000 after purchasing an additional 36 shares during the last quarter. Assetmark Inc. grew its position in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after buying an additional 43 shares during the period. Proficio Capital Partners LLC grew its position in Medpace by 6.4% during the first quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock valued at $237,000 after buying an additional 47 shares during the period. Finally, Park Avenue Securities LLC grew its position in Medpace by 1.8% during the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after buying an additional 48 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MEDP has been the subject of several recent research reports. Barclays boosted their target price on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Rothschild & Co Redburn lowered shares of Medpace from a "buy" rating to a "neutral" rating and boosted their target price for the company from $342.00 to $474.00 in a research report on Wednesday. Robert W. Baird boosted their target price on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Reduce" and an average price target of $412.73.

Medpace Price Performance

Shares of MEDP stock traded down $3.54 during mid-day trading on Thursday, hitting $477.69. The company had a trading volume of 118,644 shares, compared to its average volume of 445,490. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30. The stock's 50 day moving average price is $405.65 and its 200-day moving average price is $342.20. The company has a market capitalization of $13.42 billion, a P/E ratio of 35.53, a P/E/G ratio of 2.99 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter in the previous year, the firm earned $2.75 earnings per share. The company's quarterly revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Transactions at Medpace

In other news, CEO August J. Troendle sold 48,487 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the transaction, the chief executive officer owned 962,615 shares of the company's stock, valued at approximately $434,803,569.35. The trade was a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the company's stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $2,725,380. The trade was a 66.67% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 151,266 shares of company stock valued at $69,311,427. 20.30% of the stock is owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.